Citations

Mayo Clinic

Showing 10 of 108523 citations.

Advances from targeted therapy for non‐metastatic HER2‐positive inflammatory breast cancer
Steadman, Jessica A. , Hieken, Tina J. , Hieken, Tina J

Journal of Surgical Oncology | August 5, 2024 | Volume: 130 | Issue: 3 | Pages: 366-370

10.1002/jso.27797 | PMID 39101322 Get It

AbstractAmong inflammatory breast cancer (IBC) patients, over one‐third have HER2‐overexpressing (HER2+) tumors. Pathologic complete response (pCR) rates to neoadjuvant targeted and chemotherapy for patients with HER2+ non‐metastatic IBC now apporach 60% and favorable long‐term survival rates are being reported for those with a pCR. Immune mechanisms contributing to this phenomenon include antibody‐mediated immune activation and induction of memory T‐cell reponses which may explain the sustained antitumor response seen after discontinuation of targeted therapies.
Valvular Endocarditis and Biventricular Heart Failure in the Setting of Tropheryma whipplei Disease
Ergi, Defne Güneş , Fadel, Hind J., Lin, Grace , Greason, Kevin L. , Michelena, Héctor I. , Arghami, Arman

Texas Heart Institute Journal | August 5, 2024 | Volume: 51 | Issue: 2 | Pages: No page available

10.14503/thij-23-8336 | PMID 39101327 Get It

Abstract Whipple disease is a rare systemic illness associated with weight loss, diarrhea, and arthralgia. Asymptomatic carriage is common, but the disease can be complicated by cardiac involvement and may result in culture-negative endocarditis. Cardiac manifestations of the disease can lead to death. This report presents the case of a 66-year-old man with Whipple disease and biventricular heart failure with cardiogenic shock. Medical therapy followed by successful replacement of the aortic and mitral valves resulted in substantial improvement.
Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial
Tada, Atsushi , Burkhoff, Daniel , Naser, Jwan A. , Harada, Tomonari , Pourmussa, Bianca , Reddy, Yogesh N.V. , Jensen, Michael D. , Carter, Rickey E. , Demmer, Ryan T. , Testani, Jeffrey M. , Chirinos, Julio A. , Borlaug, Barry A , Nishimura, Rick , Carter, Rickey E , Burkhoff, Daniel , Testani, Jeffrey M , Demmer, Ryan T , Naser, Jwan A , Borlaug, Barry A.

Circulation | August 5, 2024 | Volume: 150 | Issue: 13 | Pages: 997-1009

10.1161/circulationaha.124.068788 | PMID 39101201 Get It

BACKGROUND: Systemic arterial compliance and venous capacitance are typically impaired in patients with heart failure with preserved ejection fraction (HFpEF), contributing to hemodynamic congestion with stress. Sodium-glucose cotransporter-2 inhibitors reduce hemodynamic congestion and improve clinical outcomes in patients with HFpEF, but the mechanisms remain unclear. This study tested the hypothesis that Dapagliflozin would improve systemic arterial compliance and venous capacitance during exercise in patients with HFpEF. METHODS: In this secondary analysis from the CAMEO-DAPA trial (Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial), 37 patients with HFpEF (mean age 68 ± 9 years, women 65%) underwent invasive hemodynamic exercise testing with simultaneous echocardiography at baseline and following treatment for 24 weeks with Dapagliflozin or placebo. Radial artery pressure (BP) was measured continuously using a fluid-filled catheter with transformation to aortic pressure, central hemodynamics were measured using high-fidelity micromanometers, and stressed blood volume was estimated from hemodynamic indices fit to a comprehensive cardiovascular model. RESULTS: There was no statistically significant effect of Dapagliflozin on resting BP, but Dapagliflozin reduced systolic BP during peak exercise (estimated treatment difference [ETD], −18.8 mm Hg [95% CI, −33.9 to −3.7] P =0.016). Reduction in BP was related to improved exertional total arterial compliance (ETD, 0.06 mL/mm Hg/m 2 [95% CI, 0.003–0.11] P =0.039) and aortic root characteristic impedance (ETD, −2.6 mm Hg/mL*sec [95% CI: −5.1 to −0.03] P =0.048), with no significant effect on systemic vascular resistance. Dapagliflozin reduced estimated stressed blood volume at rest and during peak exercise (ETD, −292 mm Hg [95% CI, −530 to −53] P =0.018), and improved venous capacitance evidenced by a decline in ratio of estimated stressed blood volume to total blood volume (ETD, −7.3% [95% CI, −13.3 to −1.3] P =0.020). Each of these effects of Dapagliflozin at peak exercise were also observed during matched 20W exercise intensity. Improvements in total arterial compliance and estimated stressed blood volume were correlated with decreases in body weight, and reduction in systolic BP with treatment was correlated with the change in estimated stressed blood volume during exercise (r=0.40, P =0.019). Decreases in BP were correlated with reduction in pulmonary capillary wedge pressure during exercise (r=0.56, P <0.001). CONCLUSIONS: In patients with HFpEF, treatment with Dapagliflozin improved systemic arterial compliance and venous capacitance during exercise, while reducing aortic characteristic impedance, suggesting a reduction in arterial wall stiffness. These vascular effects may partially explain the clinical benefits with sodium-glucose cotransporter-2 inhibitors in HFpEF. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04730947.
Contemporary Outcomes and Trends for the Transseptal Mitral Valve-in-Valve Procedure Using Balloon Expandable Transcatheter Valves in the United States
Goel, Kashish , Makkar, Raj , Krishnaswamy, Amar , Kapadia, Samir , Kodali, Susheel , Shah, Ashish S. , Barker, Colin M. , Xu, Ke , Dhoble, Abhijeet , Yadav, Pradeep , Rihal, Charanjit S. , Abbas, Amr E. , Kapadia, Samir , Guerrero, Mayra E , Whisenant, Brian K. , Rihal, Charanjit S. , Guerrero, Mayra

Circulation | August 5, 2024 | Volume: 150 | Issue: 19 | Pages: 1493-1504

10.1161/circulationaha.124.068847 | PMID 39101203 Get It

BACKGROUND: Previous transcatheter valve therapy registry analyses of transcatheter mitral valve in valve (MViV) replacement of degenerated bioprosthesis reported early experience in the United States. Given recent increases in transseptal MViV volumes and introduction of the SAPIEN 3 Ultra valve, it is important to determine contemporary outcomes for patients undergoing transseptal SAPIEN 3/SAPIEN 3 Ultra MViV replacement. METHODS: The Society of Thoracic Surgeons (STS)/American College of Cardiology Transcatheter Valve Therapy Registry was used to extract data for all patients undergoing transseptal SAPIEN 3/SAPIEN 3 Ultra MViV from 2015 to September 2022. Primary efficacy outcome was 1-year all-cause mortality. Secondary end points included 30-day mortality, functional class, quality of life, and mitral valve performance. Primary safety outcomes were device success and in-hospital complications. RESULTS: A total of 4243 patients with a mean±SD STS score of 9.2±7.7 underwent transseptal MViV at 455 sites. The rate of Mitral Valve Academic Research Consortium technical (96.6%) success was high, and procedural complications were low. All-cause in-hospital, 30-day, and 1-year mortality rates were 3.2%, 4.3%, and 13.4%, respectively. Significant improvements in New York Heart Association class (New York Heart Association I/II, 18% to 87%) and quality of life (Kansas City Cardiomyopathy Questionnaire score, 38 to 78) were noted at 1 year ( P <0.0001 for both) after MViV. Upon stratifying by STS scores, it was observed that the low-risk group (STS<4) had a significantly lower in-hospital mortality rate of 0.4%, whereas the intermediate-risk group (STS, 4–8) had an in-hospital mortality rate of 1.9%. From 2015 to 2022, the number of transseptal MViV cases/year increased significantly, whereas procedure times, length of stay, and intensive care unit hours shortened significantly. At the same time, there was a significant trend toward reduced in-hospital ( P =0.0005), 30-day ( P =0.004), and 1-year mortality rates ( P =0.01). CONCLUSIONS: This multicenter, prospective study reports excellent procedural outcomes, acceptable 1-year mortality rates, and a significant improvement in quality of life for patients undergoing transseptal MViV in the contemporary era. Patients in the low-risk and intermediate-risk STS score categories had significantly better outcomes compared with those in the high-risk category. MViV is a reasonable therapy for the majority of patients with degenerated bioprosthetic mitral valves, who are anatomical candidates.
Patient-Specific Distal Femoral Guides Optimize Cartilage Topography Matching in Osteochondral Allograft Transplantations
Elias, Tristan J. , Credille, Kevin , Wang, Zachary , Inoue, Nozomu , Orías, Alejandro A. Espinoza , Beals, Corey , Haneberg, Erik , Cole, Brian J. , Yanke, Adam B. , Haneberg, Erik C , Hevesi, Mario

The American Journal of Sports Medicine | August 5, 2024 | Volume: 52 | Issue: 10 | Pages: 2547-2554

10.1177/03635465241261353 | PMID 39101660 Get It

Background: Osteochondral allograft (OCA) transplantation is an important surgical technique for full-thickness chondral defects in the knee. For patients undergoing this procedure, topography matching between the donor and recipient sites is essential to limit premature wear of the OCA. Currently, there is no standardized process of donor and recipient graft matching. Purpose: To evaluate a novel topography matching technique for distal femoral condyle OCA transplantation using 3-dimensional (3D) laser scanning to create 3D-printed patient-specific instrumentation in a human cadaveric model. Study Design: Descriptive laboratory study. Methods: Human cadaveric distal femoral condyles (n = 12) underwent 3D laser scanning. An 18-mm circular osteochondral recipient defect was virtually created on the medial femoral condyle (MFC), and the position and orientation of the best topography-matched osteochondral graft from a paired donor lateral femoral condyle (LFC) were determined using an in silico analysis algorithm minimizing articular step-off distances between the edges of the graft and recipient defect. Distances between the entire surface of the OCA graft and the underneath surface of the MFC were evaluated as surface mismatch. Donor (LFC) and recipient (MFC) 3D-printed patient-specific guides were created based on 3D reconstructions of the scanned condyles. Through use of the guides, OCAs were harvested from the LFC and transplanted to the reamed recipient defect site (MFC). The post-OCA recipient condyles were laser scanned. The 360° articular step-off and cartilage topography mismatch were measured. Results: The mean cartilage step-off and graft surface mismatch for the in silico OCA transplant were 0.073 ± 0.029 mm (range, 0.005-0.113 mm) and 0.166 ± 0.039 mm (range, 0.120-0.243 mm), respectively. Comparatively, the cadaveric specimens postimplant had significantly larger step-off differences (0.173 ± 0.085 mm; range, 0.082-0.399 mm; P = .001) but equivalent graft surface topography matching (0.181 ± 0.080 mm; range, 0.087-0.396 mm; P = .678). All 12 OCA transplants had mean circumferential step-off differences less than a clinically significant cutoff of 0.5 mm. Conclusion: These findings suggest that the use of 3D-printed patient-specific guides for OCA transplantation has the ability to reliably optimize cartilage topography matching for LFC to MFC transplantation. This study demonstrated substantially lower step-off values compared with previous orthopaedic literature when also evaluating LFC to MFC transplantation. Using this novel technique in a model performing MFC to MFC transplantation has the potential to yield further enhanced results due to improved radii of curvature matching. Clinical Relevance: Topography-matched graft implantation for focal chondral defects of the knee in patients improves surface matching and has the potential to improve long-term outcomes. Efficient selection of the allograft also allows improved availability of the limited allograft sources.
An magnetic resonance imaging–pathology correlation case report of cardiac sarcoidosis mimicking arrhythmogenic biventricular cardiomyopathy
Kim, B Michelle , Bois, Melanie C. , Munoz, Freddy Del‐Carpio , Rosenbaum, Andrew , Chang, Ian C , Del-Carpio Munoz, Freddy , Rosenbaum, Andrew N , Kim, B Michelle

European Heart Journal - Case Reports | August 5, 2024 | Volume: 8 | Issue: 8 | Pages: No page available

10.1093/ehjcr/ytae395 | PMID 39156954 Get It

Abstract Background Cardiac sarcoidosis (CS) is a granulomatous disease that can manifest as conduction defects, ventricular arrhythmias, and heart failure. The diagnosis of CS is inherently difficult due to variable presentations; as such, endomyocardial biopsy is often required but lacks sensitivity due to patchy myocardial involvement. Moreover, the diagnostic criteria of CS and arrhythmogenic cardiomyopathy overlap, particularly in right-side dominant or biventricular presentations, which further complicates an already challenging differential diagnosis. Case summary A 53-year-old man with no prior chronic medical conditions presented with ventricular tachycardia (VT) and heart failure with reduced ejection fraction. He was found to have biventricular cardiomyopathy and late gadolinium enhancement on cardiac magnetic resonance imaging, resulting in an initial diagnosis of arrhythmogenic cardiomyopathy. Implantable cardioverter-defibrillator was placed, but he was readmitted for recurrent VT 2 months later. Despite an aggressive VT therapy (combination of antiarrhythmic drugs, epicardial and endocardial ablation, and stellate ganglion block), he continued with refractory VT and developed cardiogenic shock. Extra-corporeal membrane oxygenation was initiated as a bridge to heart transplantation. Pathology of the explanted heart revealed the underlying disease to be CS. Discussion Cardiac sarcoidosis can mimic arrhythmogenic biventricular cardiomyopathy and may be difficult to distinguish by the proposed diagnostic criteria. High clinical suspicion and thorough investigation are necessary for an earlier diagnosis and initiation of treatment.
The role of genetic testing in diagnosing Fabry’s disease and its overlapping with cardiomyopathies: a case series
Suppah, Mustafa , Narayanasamy, Hema, Nelson, James A. , Alsidawi, Said , Nelson, James, Alsidawi, Said , Nelson, James

European Heart Journal - Case Reports | August 5, 2024 | Volume: 8 | Issue: 8 | Pages: No page available

10.1093/ehjcr/ytae375 | PMID 39161721 Get It

Abstract Background Fabry’s disease, an X-linked lysosomal storage disorder, shares cardiac manifestations with hypertrophic cardiomyopathy (HCM). We underscore the importance of considering Fabry’s disease as a differential diagnosis in HCM patients, highlighting genetic testing’s role in cardiomyopathy evaluation. Case summary Three male patients with left ventricular hypertrophy were initially diagnosed with HCM but were later found to have Fabry’s disease through genetic testing. Atypical features such as renal dysfunction and conduction abnormalities raised suspicion. Genetic testing confirmed diagnosis, guiding tailored management. Discussion Fabry’s disease poses diagnostic challenges due to its resemblance to HCM. Genetic testing enables precise diagnosis and personalized management, especially in cases with atypical presentations. Early recognition and intervention, facilitated by genetic testing, can improve patient outcomes in Fabry’s disease.
Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network
Klyscz, Philipp , Asseyer, Susanna , Bereuter, Charlotte , Bialer, Omer , Bick, Atira, Carta, Sara , Chen, John J. , Cohen, Leila , Cohen‐Tayar, Yamit , Gernert, Jonathan A. , Haas, Julian , Heesen, Christoph , Hellmann, Mark A. , Levin, Netta , Lotan, Itay , Luis, María Belén , Vergara, Alvaro Jose Mejia, Ocampo, Cassandra, Ochoa, Susana, Oertel, Frederike Cosima , Olszewska, Maja, Uribe, José Luis Peralta , Scocco, Darío H. , Shifa, Jemal Zeberga, Simantov, Ilya, Tiosano, Alon , Torres-Camacho, Isabel , Dembinsky, Adi Vaknin, Vidal‐Jordana, Ángela , Wilf‐Yarkoni, Adi , Wu, Ti , Zamir, Sol, Zarco, Luis Alfonso , Zimmermann, Hanna , Paul, Friedemann , Dale, Russell C , Levin, Netta , Lotan, Itay , Mariotto, Sara , Oertel, Frederike C , Sastre-Garriga, Jaume , Ramanathan, Sudarshini , Rattanathamsakul, Natthapon , Shi, Fu-Dong , Tisavipat, Nanthaya , Zimmermann, Hanna G , Paul, Friedemann , Chen, John J , Carta, Sara , Alonso, Ricardo Nicolás , Contentti, Edgar Carnero , Dale, Russell C. , Flanagan, Eoin P. , Haas, Julian, Havla, Joachim , López, Pablo A. , Mariotto, Sara , Mayer, Christina , Mejía-Vergara, Álvaro J. , Ramanathan, Sudarshini , Rattanathamsakul, Natthapon , Siritho, Sasitorn , Tisavipat, Nanthaya , Petzold, Axel , Stiebel‐Kalish, Hadas

Annals of Clinical and Translational Neurology | August 5, 2024 | Volume: 11 | Issue: 9 | Pages: 2473-2484

10.1002/acn3.52166 | PMID 39099240 Get It

AbstractObjectiveThe first international consensus criteria for optic neuritis (ICON) were published in 2022. We applied these criteria to a prospective, global observational study of acute optic neuritis (ON).MethodsWe included 160 patients with a first‐ever acute ON suggestive of a demyelinating CNS disease from the Acute Optic Neuritis Network (ACON). We applied the 2022 ICON to all participants and subsequently adjusted the ICON by replacing a missing relative afferent pupillary defect (RAPD) or dyschromatopsia if magnetic resonance imaging pathology of the optical nerve plus optical coherence tomography abnormalities or certain biomarkers are present.ResultsAccording to the 2022 ICON, 80 (50%) patients were classified as definite ON, 12 (7%) patients were classified as possible ON, and 68 (43%) as not ON (NON). The main reasons for classification as NON were absent RAPD (52 patients, 76%) or dyschromatopsia (49 patients, 72%). Distribution of underlying ON etiologies was as follows: 78 (49%) patients had a single isolated ON, 41 (26%) patients were diagnosed with multiple sclerosis, 25 (16%) patients with myelin oligodendrocyte glycoprotein antibody‐associated disease, and 15 (9%) with neuromyelitis optica spectrum disorder. The application of the adjusted ON criteria yielded a higher proportion of patients classified as ON (126 patients, 79%).InterpretationAccording to the 2022 ICON, almost half of the included patients in ACON did not fulfill the requirements for classification of definite or possible ON, particularly due to missing RAPD and dyschromatopsia. Thorough RAPD examination and formal color vision testing are critical to the application of the 2022 ICON.
Resection versus resection with ablation: Analysis from the colorectal liver operative metastasis international collaborative
Mainali, Bigyan B. , Valenzuela, Cristian D. , Moaven, Omeed , Piccolo, Nico R. Del, Corvera, Carlos U. , Wisneski, Andrew D. , Zarandi, Nima Pourhabibi , Dourado, Justin , Shen, Perry , Del Piccolo, Nico R, Shen, Perry , Moaven, Omeed , Stauffer, John , Cheung, Tan To , Cha, Charles , Russell, Gregory B.

Journal of Surgical Oncology | August 5, 2024 | Volume: 130 | Issue: 3 | Pages: 516-522

10.1002/jso.27789 | PMID 39099202 Get It

AbstractBackgroundThermal ablation has recently become a key therapy for the treatment of colorectal liver metastasis (CLM). However, the role of ablation in combination with resection has not yet been firmly established. We hypothesize that in patients with CLM, those who undergo liver resection with ablation (RA) have similar outcomes compared with those who undergo liver resection only.MethodsWe reviewed a multicenter international database of 906 surgical procedures for CLM from 5 high volume hepatobiliary surgical units. Patients undergoing RA (n = 63) were matched based on the number of lesions and tumor size using a 1:1 balanced propensity score analysis with those having resection only (n = 63). Our primary outcomes were overall survival (OS) and disease‐free survival (DFS).ResultsThe mean age of our cohort was 58 ± 11 years, with 43% females. With a median follow‐up of 70.8 months, patients in the resection and RA group had a median OS of 45.1 and 54.8 months (p = 0.71), respectively. The median DFS was 22.7 and 14.2 months (p = 0.045), respectively. Using a multivariate Cox proportional hazards regression model, the treatment approach was not associated with OS (p = 0.94) or DFS (p = 0.059). A higher number of lesions is independently associated with worse DFS (hazard ratio: 1.12, p < 0.01). When there was disease recurrence, the region of recurrence was similar between the RA versus resection only groups (p = 0.27), but there was a shorter time to recurrence in the RA group (p = 0.002).ConclusionFor CLM, the treatment approach was not significantly associated with OS or DFS, while tumor biology likely played an important role. Prospective research on the quality and effectiveness of thermal ablation combined with hepatic resection is warranted.